IFNγR Signaling Mediates Alloreactive T-cell Trafficking and GVHD

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2012 Sep 14

PMID 22972985

Citations 84

Authors

Jaebok Choi

Edward D Ziga

Julie Ritchey

Lynne Collins

Julie L Prior

Matthew L Cooper

David Piwnica-Worms

John F Dipersio

Affiliations

Soon will be listed here.

Abstract

The clinical goal of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is to minimize GVHD while maintaining GvL. Here, we show that interferon γ receptor-deficient (IFNγR(-/-)) allogeneic Tconv, which possess normal alloreactivity and cytotoxicity, induce significantly less GVHD than wild-type (WT) Tconv. This effect is mediated by altered trafficking of IFNγR(-/-) Tconv to GVHD target organs, especially the gastrointestinal (GI) tract. We show that the chemokine receptor CXCR3 is induced via IFNγR-mediated signaling and partially contributes to the trafficking of WT Tconv to GVHD target organs. Indeed, CXCR3(-/-) Tconv recapitulate the reduced GVHD potential of IFNγR(-/-) Tconv in a minor-mismatched GVHD model. Most importantly, IFNγR(-/-) (and CXCR3(-/-)) Tconv mediate a robust and beneficial GvL effect. In addition, we show that IFNγR(-/-) regulatory T cells (Tregs) are fully suppressive in vitro although defective in suppressor function in vivo and that WT Tregs suppress GVHD in vivo only when allogeneic Tconv produce interferon γ (IFNγ), suggesting that the IFNγR signaling pathway is the major mechanism for both Tregs and Tconv to migrate to GVHD target organs. Finally, pharmacologic inhibition of IFNγR signaling with inhibitors of JAK1/JAK2, which are mediators of IFNγR signaling, results in the decreased expression of CXCR3 and reduced GVHD and improved survival after allo-HSCT and this effect is mediated by altered trafficking of Tconv to GVHD target organs.

Citing Articles

Targeting the chemokines in acute graft-versus-host disease.

Xu Z, Wang H Front Immunol. 2025; 15():1525244.

PMID: 39840040 PMC: 11747407. DOI: 10.3389/fimmu.2024.1525244.

Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments.

Pang Y, Nguyen W, Guerrero L, Chrisman L, Hooper M, McCarthy M Am J Clin Dermatol. 2024; 25(6):927-950.

PMID: 39348008 DOI: 10.1007/s40257-024-00886-9.

IFN-γ induces acute graft-versus-host disease by promoting HMGB1-mediated nuclear-to-cytoplasm translocation and autophagic degradation of p53.

Wang S, Cheng T, Chen X, Zeng C, Qin W, Xu Y Clin Sci (Lond). 2024; 138(20):1287-1304.

PMID: 39312196 PMC: 11479981. DOI: 10.1042/CS20241144.

Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow.

Zhao K, Zhu J, Rosenberger S, Rosenberger S, Zhou M, Shlomchik W Blood Adv. 2024; 9(1):209-221.

PMID: 39172160 PMC: 11788131. DOI: 10.1182/bloodadvances.2024013291.

Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.

Denk A, Edinger M, Weber D, Holler E, Fante M, Meedt E Ann Hematol. 2024; 103(8):3071-3081.

PMID: 38916740 PMC: 11283387. DOI: 10.1007/s00277-024-05696-x.

References

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V . Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009; 69(5):2000-9. DOI: 10.1158/0008-5472.CAN-08-2360. View

Khattri R, Cox T, Yasayko S, Ramsdell F . An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003; 4(4):337-42. DOI: 10.1038/ni909. View

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman C, Strober S . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; 9(9):1144-50. DOI: 10.1038/nm915. View

Mowat A . Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology. 1989; 68(1):18-23. PMC: 1385499. View

Betts B, Abdel-Wahab O, Curran S, St Angelo E, Koppikar P, Heller G . Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood. 2011; 118(19):5330-9. PMC: 3217413. DOI: 10.1182/blood-2011-06-363408. View

Iwasaki M, Mukai T, Nakajima C, Yang Y, Gao P, Yamaguchi N . A mandatory role for STAT4 in IL-12 induction of mouse T cell CCR5. J Immunol. 2001; 167(12):6877-83. DOI: 10.4049/jimmunol.167.12.6877. View

Wilson L . Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat. 2010; 20(5):609-23. DOI: 10.1517/13543771003709767. View

Yang Y, Qi J, Wang M, Sykes M . Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood. 2002; 99(11):4207-15. DOI: 10.1182/blood.v99.11.4207. View

He S, Cao Q, Qiu Y, Mi J, Zhang J, Jin M . A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody. J Immunol. 2008; 181(11):7581-92. DOI: 10.4049/jimmunol.181.11.7581. View

10.

Welniak L, Blazar B, Anver M, Wiltrout R, Murphy W . Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning. Biol Blood Marrow Transplant. 2000; 6(6):604-12. DOI: 10.1016/s1083-8791(00)70025-5. View

11.

Gondek D, Lu L, Quezada S, Sakaguchi S, Noelle R . Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005; 174(4):1783-6. DOI: 10.4049/jimmunol.174.4.1783. View

12.

Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D . Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009; 114(14):3101-12. PMC: 2756212. DOI: 10.1182/blood-2009-05-219402. View

13.

Swihart K, Fruth U, Messmer N, Hug K, BEHIN R, Huang S . Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med. 1995; 181(3):961-71. PMC: 2191906. DOI: 10.1084/jem.181.3.961. View

14.

Gross S, Piwnica-Worms D . Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods. 2005; 2(8):607-14. DOI: 10.1038/nmeth779. View

15.

Kernan N, Collins N, Juliano L, Cartagena T, DuPont B, OReilly R . Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986; 68(3):770-3. View

16.

Butturini A, Gale R . The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant. 1987; 2(4):351-4. View

17.

Lu Y, Waller E . Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant. 2009; 15(11):1347-53. PMC: 2782586. DOI: 10.1016/j.bbmt.2009.07.015. View

18.

Hasegawa H, Inoue A, Kohno M, Lei J, Miyazaki T, Yoshie O . Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model. Gene Ther. 2007; 15(3):171-82. DOI: 10.1038/sj.gt.3303051. View

19.

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

20.

Lu B, Ebensperger C, Dembic Z, Wang Y, Kvatyuk M, Lu T . Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proc Natl Acad Sci U S A. 1998; 95(14):8233-8. PMC: 20959. DOI: 10.1073/pnas.95.14.8233. View